Trials / Unknown
UnknownNCT04132674
Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Vancouver Infectious Diseases Centre · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
In an effort to engage more HIV-infected PWUD into care, and ensure treatment adherence and efficacy, simplification of older, multi-tablet regimens is required. Newer, more potent molecules can also overcome resistant that has persisted with previous regimens, while simultaneously providing a high barrier to resistance. The co-formulation of B/F/TAF is a viable switch-option for patients who have experienced lower adherence with previous regimens due to high pill burden, or for those requiring a more potent regimen due to emergent resistances. The formal evaluation of B/F/TAF in this context will allow us to optimize care for HIV-infected PWUD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bictegravir/emtricitabine/tenofovir alafenamide | Taking one oral tablet of B/F/TAF once-daily for 72 weeks |
Timeline
- Start date
- 2018-11-26
- Primary completion
- 2020-06-30
- Completion
- 2020-12-31
- First posted
- 2019-10-21
- Last updated
- 2019-10-21
Locations
2 sites across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04132674. Inclusion in this directory is not an endorsement.